CMPS vs. RCKT, PSTX, BCYC, OCS, CVAC, COGT, ABCL, PAHC, NUVB, and AVBP
Should you be buying COMPASS Pathways stock or one of its competitors? The main competitors of COMPASS Pathways include Rocket Pharmaceuticals (RCKT), Poseida Therapeutics (PSTX), Bicycle Therapeutics (BCYC), Oculis (OCS), CureVac (CVAC), Cogent Biosciences (COGT), AbCellera Biologics (ABCL), Phibro Animal Health (PAHC), Nuvation Bio (NUVB), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical products" industry.
COMPASS Pathways vs.
Rocket Pharmaceuticals (NASDAQ:RCKT) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation, community ranking and earnings.
Rocket Pharmaceuticals' return on equity of -62.62% beat COMPASS Pathways' return on equity.
Rocket Pharmaceuticals received 330 more outperform votes than COMPASS Pathways when rated by MarketBeat users. However, 80.26% of users gave COMPASS Pathways an outperform vote while only 73.22% of users gave Rocket Pharmaceuticals an outperform vote.
Rocket Pharmaceuticals currently has a consensus price target of $47.27, suggesting a potential upside of 351.08%. COMPASS Pathways has a consensus price target of $33.60, suggesting a potential upside of 800.80%. Given COMPASS Pathways' stronger consensus rating and higher probable upside, analysts plainly believe COMPASS Pathways is more favorable than Rocket Pharmaceuticals.
Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks.
Rocket Pharmaceuticals has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500.
In the previous week, COMPASS Pathways had 4 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 7 mentions for COMPASS Pathways and 3 mentions for Rocket Pharmaceuticals. COMPASS Pathways' average media sentiment score of 0.44 beat Rocket Pharmaceuticals' score of 0.23 indicating that COMPASS Pathways is being referred to more favorably in the news media.
98.4% of Rocket Pharmaceuticals shares are held by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are held by institutional investors. 28.5% of Rocket Pharmaceuticals shares are held by company insiders. Comparatively, 4.3% of COMPASS Pathways shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
COMPASS Pathways beats Rocket Pharmaceuticals on 10 of the 15 factors compared between the two stocks.
Get COMPASS Pathways News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMPS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
COMPASS Pathways Competitors List
Related Companies and Tools
This page (NASDAQ:CMPS) was last updated on 1/22/2025 by MarketBeat.com Staff
Free CMPS Stock Alerts